학술논문

The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study
Document Type
Article
Source
In Heliyon 15 October 2024 10(19)
Subject
Language
ISSN
2405-8440
Abstract
Conclusions We found that no matter CDK4/6i or EVE was used first, the survival were not significantly different between Group A and Group B. Both can be clinical options.